Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial
Lancet. 2024;9:981–96 doi: 10.1016/S2468-1253(24)00200-0
Choy et al. investigated the efficacy and safety of intensified versus standard infliximab dosing for steroid-refractory acute severe ulcerative colitis (ASUC). The study found that a first dose of 10mg/kg infliximab was not superior to the standard 5mg/kg dose in achieving clinical response by Day 7. Earlier responses were noted with dose intensification, but no significant differences were observed in remission, colectomy rates, or safety profiles by Month 3.
The open-label, multicentre, randomised controlled trial enrolled 138 patients across 13 Australian tertiary hospitals to compare induction and maintenance strategies for infliximab in ASUC. The trial explored outcomes such as colectomy-free survival, adverse events, and the impact of infliximab on endoscopic remission.
Keywords:
